Molecular Testing Improves Nodular Fasciitis Diagnosis
USP6 analysis helps resolve uncertainty in atypical soft-tissue lesions
-
By
-
Andrea Surnit
-
April 3, 2026
-
Clinical Scorecard: Molecular Testing Improves Nodular Fasciitis Diagnosis
At a Glance
| Category | Detail |
| Condition | Nodular Fasciitis |
| Key Mechanisms | USP6 rearrangements identified through molecular testing. |
| Target Population | Patients with soft-tissue lesions suspected to be nodular fasciitis. |
| Care Setting | Pathology and diagnostic laboratories. |
Key Highlights
- Molecular testing identified USP6 rearrangements in all non-specific cases.
- 66% of cases did not initially raise suspicion for nodular fasciitis.
- Fluorescence in situ hybridization detected rearrangements in 83% of tested cases.
- Next-generation sequencing resolved inconclusive cases with USP6 gene fusions.
- Atypical fusions were found in younger patients compared to common fusions.
Guideline-Based Recommendations
Diagnosis
- Utilize molecular testing for cases with inconclusive morphology or clinicopathological discordance.
Management
- Confirm diagnosis through histopathology, immunohistochemistry, and molecular testing.
Monitoring & Follow-up
- Monitor for symptoms and histologic features consistent with nodular fasciitis.
Risks
- Misdiagnosis as more aggressive tumors due to non-specific presentations.
Patient & Prescribing Data
Mean age of 34 years, with no sex predominance.
Patients may present with pain or neurologic deficits rather than superficial masses.
Clinical Best Practices
- Incorporate molecular diagnostics in the evaluation of soft-tissue lesions.
- Recognize atypical presentations of nodular fasciitis to improve diagnostic confidence.
References